{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
amphotericin b
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Piriprost (U-60, 257) is a structural analog of prostaglandin I2 (PGI2) with low IP receptor-mediated activity. It inhibits 5-LO (5-lipoxygenase). Piriprost inhibits the release of histamine and leukotrienes, implicating its role in inflammation and allergic responses. However, it was shown, that piriprost did not influence the airway responses after allergen in asthma. Nevertheless, even more, the drug was irritant to the respiratory tract than was placebo.
Status:
Investigational
Source:
NCT00151736: Phase 2 Interventional Terminated Chronic Lymphocytic Leukemia
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
R-etodolac (SDX-101) is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid). The absolute configuration of the enantiomer is R-(-)-etodolac. R-etodolac specifically bound retinoid X receptor (RXRalpha), inhibited RXRalpha transcriptional activity, and induced its degradation by a ubiquitin and proteasome-dependent pathway. In addition R-etodolac can disrupt the beta-catenin signaling pathway. R-etodolac exerts antineoplastic properties. R-etodolac was in phase 2 studies for the treatment of hematologic malignancies however development was discontinued.
Status:
Investigational
Source:
NCT00597818: Phase 2 Interventional Completed NSAID-induced Gastroduodenal Injury
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cobristone is a locally acting chloride channel activator that works to stimulate and protect the mucosal barrier function. Cobristone is being developed by the Sucampo Pharmaceuticals, Inc. for the prevention of oral mucositis and for the treatment of non-erosive reflux disease (NERD), a major subtype of gastroesophageal reflux disease. The development of the drug was terminated after phase 2 clinical trials failed to meet its primary endpoints.
Status:
Investigational
Source:
NCT00002422: Phase 1 Interventional Completed HIV Infections
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
16alpha-Bromoepiandrosterone (HE2000) is a synthetic steroid that limits non-productive inflammation, enhances protective immunity and improves survival in clinical studies of patients with human immunodeficiency virus (HIV), malaria and tuberculosis infections. HE 2000 had also shown activity in vitro against cytomegalovirus, polio, hepatitis B and C and influenza virus. 16alpha-Bromoepiandrosterone inhibits glucose-6-phosphate dehydrogenase (G6PD) and cell proliferation. HE 2000 was in phase II development for the Hepatitis B in Malaysia and Singapore, but it was suspended.
Status:
Investigational
Source:
NCT00113308: Phase 3 Interventional Completed Arthritis, Rheumatoid
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
GW406381 is an investigational, highly selective cyclooxygenase-2 (COX-2) inhibitor for inflammatory pain treatment. It showed effectiveness in animal models of central sensitization such as chronic constriction injury and capsaicin-induced hyperalgesia. It's effect was also evaluated in several clinical trials in patients with peripheral nerve injury (Phase I ), rheumatoid arthritis (Phase III), the signs and symptoms of osteoarthritis of the knee to control of pain and improvement in function (Phase III), and in treating the signs and symptoms of dental pain following third molar tooth extraction (Phase III). Possessing favourable pharmacokinetic profiles and analgesic activity in vivo, GW406381 have also demonstrated relatively high brain penetration in the rat compared with the clinically available compounds, which may ultimately prove beneficial in the treatment of pain.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Furazolium, an antibacterial agent, was studied for the management of skin infections. However, information about the current use of this drug is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Homopipramol, a neuroleptic agent, was used as an antidepressant. This compound has never been marketed.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nicodicodine is a cough suppressant and analgesic. It was first synthesized in 1904. It is a Schedule III drug. Nicodicodine is metabolised in the liver to dihydromorphine. Since the final active metabolite is the slightly stronger opiate than morphine, nicodicodine can be expected to be more potent and longer acting than nicocodeine.
Class (Stereo):
CHEMICAL (MIXED)
Morazone is is a nonsteroidal anti-inflammatory drug (NSAID), originally developed by the German pharmaceutical company Ravensberg in the 1950s. Morazone was used as a moderately strong analgesic but was discontinued due to high abuse potential
